CN101502496B - Method for preparing norfloxacin capsule - Google Patents
Method for preparing norfloxacin capsule Download PDFInfo
- Publication number
- CN101502496B CN101502496B CN2009100611678A CN200910061167A CN101502496B CN 101502496 B CN101502496 B CN 101502496B CN 2009100611678 A CN2009100611678 A CN 2009100611678A CN 200910061167 A CN200910061167 A CN 200910061167A CN 101502496 B CN101502496 B CN 101502496B
- Authority
- CN
- China
- Prior art keywords
- norfloxacin
- beta
- vacuum
- drying
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960001180 norfloxacin Drugs 0.000 title claims abstract description 60
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 239000002775 capsule Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000000227 grinding Methods 0.000 claims abstract description 6
- 229950005162 benexate Drugs 0.000 claims description 11
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 11
- 238000001291 vacuum drying Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 7
- 235000011837 pasties Nutrition 0.000 claims description 7
- 238000003801 milling Methods 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 3
- 239000001116 FEMA 4028 Substances 0.000 abstract 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 3
- 229960004853 betadex Drugs 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000011049 filling Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000004570 mortar (masonry) Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000005498 polishing Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a method for preparing norfloxacin capsules, which comprises the following steps: (1) evenly stirring norfloxacin and beta-cyclodextrin by the substance ratio of norfloxacin to Beta-cyclodextrin being 1:1, then, adding water and evenly grinding the mixture into paste for 6 to 10 hours at the temperature of 20 to 35 DEG C until the norfloxacin/Beta-cyclodextrin inclusion compound is formed; (2) tiling and drying the inclusion compound at the temperature of 45 to 60 DEG C; (3) pulverizing the dried inclusion compound, granulating the ground medicine through a 80-mesh sieve and drying at the temperature of 45 to 60 DEG C until the water content is lower than 9%; and (4) measuring the norfloxacin content of the granules, converting and filling a No.0 empty capsule with the granules to ensure that each granule contains 0.1g of norfloxacin, and finally packaging to obtain the norfloxacin capsules. The product of the invention has good water-solubility and improves the bioavailability and the stability.
Description
Technical field
The present invention relates to the preparation method of norfloxacin capsule.
Background technology
Norfloxacin is a fluoroquinolone antibacterial agent, the tool broad-spectrum antibacterial action, especially to the antibacterial activity height of aerobic gram negative bacilli, to following antibacterial at the good antibacterial action of external tool: most of antibacterial of enterobacteriaceae comprises Enterobacters such as bacillus citrate genus, enterobacter cloacae, clostridium perfringen, escherichia coli, Klebsiella, proteus, Salmonella, Shigella, vibrio, yersinia etc.Norfloxacin is external also has an antibacterial activity to multi-drug resistant bacteria.The drug-fast Diplococcus gonorrhoeae of penicillin, hemophilus influenza and moraxelle catarrhalis also there is good antibacterial action.Norfloxacin is an antibacterial, by acting on the A subunit of DNA of bacteria helicase, suppresses the synthetic of DNA and duplicates and cause antibacterial death.Be applicable to urinary tract infection, gonorrhea, prostatitis, intestinal infection and typhoid fever and other Salmonella infection due to the sensitive organism.
But norfloxacin is insoluble in water, oral administration biaavailability low (about 50%), and bitter in the mouth, and character is also unstable, meets the oxidable decomposition of light.
Summary of the invention
The object of the present invention is to provide a kind of preparation method of norfloxacin capsule, the product of this method preparation increases its dissolubility and dissolution greatly, has quickened the release of norfloxacin, improves its bioavailability greatly, and has improved its stability.
Technical scheme provided by the invention is: the preparation method of norfloxacin capsule, comprise 1. by norfloxacin: the amount ratio of beta-schardinger dextrin-=1: 1, get norfloxacin and beta-schardinger dextrin-mix homogeneously, and then add water and grind well into pasty state, ground 6～10 hours, grinding temperature is 20～35 ℃, to forming the norfloxacin Benexate Hydrochloride; 2. with clathrate tiling, 45～60 ℃ of oven dry; 3. the medicine of oven dry is pulverized, crossed 80 mesh sieves and granulate, 45～60 ℃ are dried to and contain moisture below 9%; 4. measure granule norfloxacin content, insert capsulae vacuus after the conversion No. 0, make every to contain norfloxacin 0.1g, packing promptly gets norfloxacin capsule at last.
The milling time of above-mentioned steps in 1. is 8～10 hours, and grinding temperature is 20～25 ℃; The oven dry of step in 2. is 50 ± 2 ℃ of vacuum dryings in the drying under reduced pressure case; The drying of step in 3. is 50 ± 2 ℃ of vacuum dryings in the drying under reduced pressure case.
The vacuum of the vacuum drying of above-mentioned steps in 2. is 2 * 10
4～5 * 10
4Pa; The vacuum drying vacuum of step in 3. is 2 * 10
4～5 * 10
4Pa.
The present invention by with polishing norfloxacin being made Benexate Hydrochloride earlier, is prepared into capsule with clathrate owing to adopt technique scheme again.Product stripping, the rate of release of this method preparation are fast, the bioavailability height, and stability strengthens.
This law adopts polishing that norfloxacin is made Benexate Hydrochloride to prepare the norfloxacin Benexate Hydrochloride with the employing neutralisation and compare, and the polishing inclusion rate is 82-84%, and the neutralisation inclusion rate is 68-71%.Neutralisation prepares clathrate, and yield difference is big, and its reason is whether pH value is the key of this technology accurately, next reaction temperature, rate of charge, mixing time has considerable influence to its inclusion rate, and washing and filtering can influence yield, and this technology solvent for use is strong acid, highly basic, working condition is required high.In clathrate preparation, the dry run, if temperature is higher, clathrate stability reduces, the clathrate flavescence, even take off bag.This method control grinding temperature, adopt vacuum dehydrating at lower temperature, and shorten drying time, help improving the inclusion rate, clathrate is free of losses almost, it is about 12% that its inclusion rate is higher than neutralisation, and the yield height, system easy to control the quality, stable content, having repeatability preferably, is an inclusion method preferably, and more is applicable to the industrialized great production of clathrate.
This method inclusion rate height, system easy to control the quality, stable content.To adopt polishing to prepare the norfloxacin Benexate Hydrochloride and the norfloxacin raw material carries out 10 days stability observings under high temperature, high humidity and high illumination, the results are shown in Table 1:
Table 1 was through 10 days study on the stability results
The stripping of clathrate is obviously accelerated in the body, the accumulation stripping quantity is 99.3% (commercially available capsule is 54.46%) in 5 minutes, and peak time is fast, and commercially available capsule bioavailability is about 50%, adopt the capsule bioavailability of clathrate preparation to reach more than 90%, can effectively improve clinical efficacy.
The specific embodiment
The embodiment that below provides will help to understand the present invention, but not limit content of the present invention.
Embodiment 1:
1. get norfloxacin and beta-schardinger dextrin-(norfloxacin: beta-schardinger dextrin-=1: 1mol/mol) place abundant mix homogeneously in the mortar, and then add water and grind well into pasty state, constantly ground 6 hours, temperature is controlled to be 30 ℃ to forming the norfloxacin Benexate Hydrochloride.2. with the clathrate tiling, place under 60 ℃ of temperature of baking oven and dried by the fire 7～8 hours, to bone dry.3. the medicine of oven dry is pulverized, crossed 80 mesh sieves and granulate, be dried to moisture below 9% in 60 ℃.4. measure norfloxacin content, insert capsulae vacuus after the conversion No. 0, make every to contain norfloxacin 0.1g, packing promptly at last.
The inclusion rate is 70%.The accumulation stripping quantity is 99.3% in 5 minutes.
Embodiment 2:
1. get norfloxacin and beta-schardinger dextrin-(norfloxacin: beta-schardinger dextrin-=1: 1mol/mol) place abundant mix homogeneously in the mortar, and then add water and grind well into pasty state, constantly ground 10 hours, temperature is controlled to be 20～25 ℃, to forming the norfloxacin Benexate Hydrochloride.2. with the clathrate tiling, place vacuum drying under 50 ℃ of temperature of drying under reduced pressure case, dried by the fire 3～4 hours, to bone dry.3. the medicine of oven dry is pulverized, crossed 80 mesh sieves and granulate, place vacuum (2 * 10 under 50 ℃ of temperature of drying under reduced pressure case
4～3 * 10
4Pa), be dried to moisture below 9%.4. measure norfloxacin content, insert capsulae vacuus after the conversion No. 0, make every to contain norfloxacin 0.1g, packing promptly at last.
The inclusion rate is 84%.The accumulation stripping quantity is 99.5% in 5 minutes.
Embodiment 3:
1. get norfloxacin and beta-schardinger dextrin-(norfloxacin: beta-schardinger dextrin-=1: 1mol/mol) place abundant mix homogeneously in the mortar, and then add water and grind well into pasty state, constantly ground 10 hours, temperature is controlled to be 30 ℃, to forming the norfloxacin Benexate Hydrochloride.2. with the clathrate tiling, place under 60 ℃ of temperature of baking oven and dry by the fire to bone dry.3. the medicine of oven dry is pulverized, crossed 80 mesh sieves and granulate, be dried to moisture below 9% in 60 ℃.4. measure norfloxacin content, insert capsulae vacuus after the conversion No. 0, make every to contain norfloxacin 0.1g, packing promptly at last.
The inclusion rate is 74%.The accumulation stripping quantity is 99.2% in 5 minutes.
Embodiment 4:
1. get norfloxacin and beta-schardinger dextrin-(norfloxacin: beta-schardinger dextrin-=1: 1mol/mol) place abundant mix homogeneously in the mortar, and then add water and grind well into pasty state, constantly ground 8 hours, temperature is controlled to be 20～25 ℃, to forming the norfloxacin Benexate Hydrochloride.2. with the clathrate tiling, place vacuum drying under 50 ℃ of temperature of drying under reduced pressure case, to bone dry.3. the medicine of oven dry is pulverized, crossed 80 mesh sieves and granulate, place vacuum (3 * 10 under 50 ℃ of temperature of drying under reduced pressure case
4～4 * 10
4Pa) be dried to moisture below 9%.4. measure norfloxacin content, insert capsulae vacuus after the conversion No. 0, make every to contain norfloxacin 0.1g, packing promptly at last.
The inclusion rate is 82%.The accumulation stripping quantity is 99.4% in 5 minutes.P=1 * 10
5(1-O/0.1)=1 * 10
5Pa=1 atmospheric pressure
Embodiment 5:
1. get norfloxacin and beta-schardinger dextrin-(norfloxacin: beta-schardinger dextrin-=1: 2mol/mol) place abundant mix homogeneously in the mortar, and then add water and grind well into pasty state, constantly ground 8 hours, temperature is controlled to be 20～25 ℃, to forming the norfloxacin Benexate Hydrochloride.2. with the clathrate tiling, place vacuum drying under 50 ℃ of temperature of drying under reduced pressure case, to bone dry.3. the medicine of oven dry is pulverized, crossed 80 mesh sieves and granulate, place vacuum (4 * 10 under 50 ℃ of temperature of drying under reduced pressure case
4～5 * 10
4Pa) be dried to moisture below 9%.4. measure norfloxacin content, insert capsulae vacuus after the conversion No. 0, make every to contain norfloxacin 0.1g, packing promptly at last.
The inclusion rate is 81%.The accumulation stripping quantity is 99.1% in 5 minutes.
Claims (3)
1. the preparation method of norfloxacin capsule, comprise 1. by norfloxacin: the amount ratio of beta-schardinger dextrin-=1: 1, get norfloxacin and beta-schardinger dextrin-mix homogeneously, and then add water and grind well into pasty state, ground 6～10 hours, grinding temperature is 20～35 ℃, to forming the norfloxacin Benexate Hydrochloride; 2. with clathrate tiling, 45～60 ℃ of oven dry; 3. the medicine of oven dry is pulverized, crossed 80 mesh sieves and granulate, 45～60 ℃ are dried to and contain moisture below 9%; 4. measure granule norfloxacin content, insert capsulae vacuus after the conversion No. 0, make every to contain norfloxacin 0.1g, packing promptly gets norfloxacin capsule at last.
2. method according to claim 1 is characterized in that: the milling time of step in 1. is 8～10 hours, and grinding temperature is 20～25 ℃; The oven dry of step in 2. is 50 ± 2 ℃ of vacuum dryings in the drying under reduced pressure case; The drying of step in 3. is 50 ± 2 ℃ of vacuum dryings in the drying under reduced pressure case.
3. method according to claim 2 is characterized in that: the vacuum of the vacuum drying of step in 2. is 2 * 10
4～5 * 10
4Pa; The vacuum drying vacuum of step in 3. is 2 * 10
4～5 * 10
4Pa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100611678A CN101502496B (en) | 2009-03-18 | 2009-03-18 | Method for preparing norfloxacin capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100611678A CN101502496B (en) | 2009-03-18 | 2009-03-18 | Method for preparing norfloxacin capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101502496A CN101502496A (en) | 2009-08-12 |
| CN101502496B true CN101502496B (en) | 2011-01-19 |
Family
ID=40974958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100611678A Expired - Fee Related CN101502496B (en) | 2009-03-18 | 2009-03-18 | Method for preparing norfloxacin capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101502496B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101954089A (en) * | 2010-09-08 | 2011-01-26 | 洛阳惠中兽药有限公司 | Animal medicine inclusion compound, preparation method and application thereof |
| CN104606165A (en) * | 2015-02-04 | 2015-05-13 | 上海华源安徽仁济制药有限公司 | Norfloxacin capsules and preparation method thereof |
| CN106389376A (en) * | 2016-08-31 | 2017-02-15 | 安徽省润生医药股份有限公司 | Norfloxacin capsules and preparation method thereof |
| CN112336701A (en) * | 2020-11-02 | 2021-02-09 | 迪沙药业集团有限公司 | Norfloxacin capsule and preparation method thereof |
-
2009
- 2009-03-18 CN CN2009100611678A patent/CN101502496B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101502496A (en) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101816635B (en) | Cephalosporin suspension granule and preparation method thereof | |
| US20080014280A1 (en) | Amorphous pregabalin and process for the preparation thereof | |
| CN101502496B (en) | Method for preparing norfloxacin capsule | |
| CA2424462A1 (en) | Clavulanic acid pharmaceutical compositions | |
| CN102600132B (en) | Oral preparation containing amisulpride | |
| JPH11322802A (en) | Hydroxypropylcellulose having low substitution degree and its production | |
| CN102993043A (en) | Method for preparing high-purity tetracycline hydrochloride | |
| CN103110595B (en) | Cefdinir dispersible tablet and preparation method thereof | |
| CN101658255B (en) | Bee pollen powder and preparation method thereof | |
| CN103524533A (en) | Cefprozil compound, and dispersible tablets, dry suspension and preparation method thereof | |
| CN103446075A (en) | Cefaclor capsule and preparation method thereof | |
| CN103864690A (en) | S crystal form of ivabradine hydrochloride, and preparation method and pharmaceutical composition thereof | |
| CN104447795A (en) | Cefadroxil compound and pharmaceutical composition comprising same | |
| CN110251467A (en) | A kind of preparation method of amorphous state Cefditoren pivoxil Cephalosporins composition | |
| CN101759708B (en) | Cefodizime sodium crystal form and preparation method thereof as well as drug compound comprising crystal form | |
| CN101984970A (en) | Dihydroartemisinin piperaquine phosphate tablets and preparation process thereof | |
| CN1319533C (en) | Cefetamet pivoxil hydrochloride dispersion dispersion tablets and preparation method | |
| CN104173310A (en) | Stable amoxicillin tablet composition, as well as preparation method and application thereof | |
| US20080014263A1 (en) | Amorphous eprosartan mesylate and process for the preparation thereof | |
| CN103467492B (en) | Aspoxicillin compound, pharmaceutical composition, preparation and preparation method thereof | |
| CN101904826A (en) | Arbidol HCl orally disintegrating tablet and preparation method thereof | |
| CN103497204A (en) | Cefdinir compound, as well as dispersible tablets and preparation method thereof | |
| CN103405782A (en) | Inclusion compound containing celecoxib and preparation method thereof | |
| CN102232955B (en) | The preparation method of amorphous cefuroxin axetil Perorally administrable antimicrobial composition and the compositions of preparation, compound preparation | |
| CN102133203B (en) | Lacidipine dispersible tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HUANG HONG Free format text: FORMER OWNER: FAN SHAOJING Effective date: 20101119 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Huang Hong Inventor after: Fan Shaojing Inventor after: Hao Qinghua Inventor after: Yu Pingping Inventor after: Wang Shaohua Inventor before: Fan Shaojing Inventor before: Hao Qinghua Inventor before: Yu Pingping Inventor before: Wang Shaohua |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430074 (CARE OF) HUANG HONG, BIOLOGICAL ENGINEERING DEPARTMENT OF WUHAN INSTITUTE OF TECHNOLGOY, NO. 463, GUANSHAN AVENUE, HONGSHAN DISTRICT, WUHAN CITY, HUBEI PROVINCE TO: 430074 BIOLOGICAL ENGINEERING DEPARTMENT OF WUHAN POLYTECHNIC UNIVERSITY, NO. 463, GUANSHAN AVENUE, HONGSHAN DISTRICT, WUHAN CITY, HUBEI PROVINCE Free format text: CORRECT: INVENTOR; FROM: FAN SHAOJING HAO QINGHUA YU PINGPING WANG SHAOHUA TO: HUANG HONG FAN SHAOJING HAO QINGHUA YU PINGPING WANG SHAOHUA |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20101119 Address after: 430074 Hubei Province, Wuhan city Hongshan District Guanshan Road No. 463 Wuhan Polytechnic Institute of biological engineering Applicant after: Huang Hong Address before: 430074 Hubei Province, Wuhan city Hongshan District Guanshan Road No. 463 Huang Hongzhuan Institute of biological engineering Wuhan Polytechnic Applicant before: Fan Shaojing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WUHAN VOCATIONAL + TECHNICAL COLLEGE Free format text: FORMER OWNER: HUANG HONG Effective date: 20110725 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430074 SCHOOL OF BIOLOGICAL ENGINEERING, WUHAN POLYTECHNIC, NO. 463, GUANSHAN AVENUE, HONGSHAN DISTRICT, WUHAN CITY, HUBEI PROVINCE TO: 430074 NO. 463, GUANSHAN AVENUE, HONGSHAN DISTRICT, WUHAN CITY, HUBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110725 Address after: 463 No. 430074 Hubei province Wuhan city Hongshan District Kuanshan Avenue Patentee after: Wuhan Polytechnic Address before: 430074 Hubei Province, Wuhan city Hongshan District Guanshan Road No. 463 Wuhan Polytechnic Institute of biological engineering Patentee before: Huang Hong |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110119 Termination date: 20120318 |